Intellia Therapeutics

The $2B valuation pioneer of in vivo CRISPR gene editing, delivering gene corrections directly inside the human body. Its NTLA-2001 program for transthyretin amyloidosis showed landmark results with a single infusion, achieving 90% reduction in serum TTR protein levels -- 20% higher than the runner-up, Intellia's older approach.